journal
Corticosteroids for COVID-19: The Search for an Optimum Duration of Therapy
Area/Stream: Medicine, Authors: Gyanshankar P Mishra, Jasmin Mulani Keywords: Corticosteroids, COVID-19Journal Name: The Lancet Respiratory Medicine Year:2020, Month:November, Volume: 9, Issue: 1 Page No: 8, ISSN: 2213-2619, DOI/Link: https://www.thelancet.com/article/S2213-2600(20)30530-0/fulltextAbstract:
Michael A Matthay and B Taylor Thompson have very nicely summarised the evidence-based role of dexamethasone in hospitalised patients with COVID-19. Their pertinent analysis is based on the background of the RECOVERY trial, which concluded that therapy with dexamethasone at a dose of 6 mg once daily for up to 10 days decreased 28-day mortality in patients with COVID-19 on respiratory support. Patients not requiring oxygen showed no benefit but had a possibility of harm with corticosteroid therapy. One crucial feature of corticosteroid therapy is its duration, particularly in patients with COVID-19 with sustained persistence of ground-glass opacities. Currently, an extended course of corticosteroids beyond 10 days is considered only in select cases of severe COVID-19.3 One rationale for prolonged treatment is the prevention of post-disease fibrosis in patients with COVID-19 for whom risk factors for pulmonary fibrosis might be established.
Cite this: Gyanshankar P Mishra, Jasmin Mulani,"Corticosteroids for COVID-19: The Search for an Optimum Duration of Therapy", The Lancet Respiratory Medicine, 9, 1, November, 2020, 8, 2213-2619, https://www.thelancet.com/article/S2213-2600(20)30530-0/fulltext
Views: 4283
Download File
News
